

1 Tryptophan metabolism determines outcome in tuberculous meningitis: a
2 targeted metabolomic analysis

3

4 Edwin Ardiansyah^{1,2}, Julian Avila Pacheco³, Le Thanh Hoang Nhat⁴, Sofiati Dian^{1,6}, Dao Nguyen
5 Vinh⁴, Hoang Thanh Hai⁴, Kevin Bullock³, Bacht Alisjahbana^{1,5}, Mihai G Netea², Riwanti Estiasari⁷,
6 Trinh Thi Bich Tram⁴, Joseph Donovan^{4,8,9}, Dorothee Heemskerk¹⁰, Tran Thi Hong Chau^{4,11},
7 Nguyen Duc Bang¹², Ahmad Rizal Ganiem^{1,6}, Rovina Ruslami^{1,13}, Valerie ACM Koeken^{2,14}, Raph L
8 Hamers¹⁵, Darma Imran⁷, Kartika Maharani⁷, Vinod Kumar², Clary B. Clish³, Reinout van Crevel², Guy
9 Thwaites^{4,8}, Arjan van Laarhoven^{2,*,#} & Nguyen Thuy Thuong Thuong^{4,8*}

10 * equal contribution

11 # corresponding author

12 **Affiliations**

- 13 1. Research Center for Care and Control of Infectious Diseases, Universitas Padjadjaran, Bandung,
14 Indonesia
- 15 2. Department of Internal Medicine and Radboud Center of Infectious Diseases (RCI), Radboud
16 University Medical Center, Nijmegen, Netherlands
- 17 3. The Broad Institute of MIT and Harvard, Cambridge, MA, USA
- 18 4. Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam;
- 19 5. Department of Internal Medicine, Hasan Sadikin Hospital, Faculty of Medicine, Universitas
20 Padjadjaran, Bandung, Indonesia
- 21 6. Department of Neurology, Hasan Sadikin Hospital, Faculty of Medicine, Universitas Padjadjaran,
22 Bandung, Indonesia
- 23 7. Department of Neurology, Cipto Mangunkusumo Hospital, Faculty of Medicine Universitas Indonesia
- 24 8. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of
25 Oxford, Oxford, United Kingdom
- 26 9. London School of Hygiene and Tropical Medicine, Keppel St, London, United Kingdom
- 27 10. Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical
28 Centre, Amsterdam, the Netherlands
- 29 11. Hospital for Tropical Diseases, District 5, Ho Chi Minh City, Vietnam
- 30 12. Pham Ngoc Thach Hospital for Tuberculosis and Lung Disease, District 5, Ho Chi Minh City, Vietnam
- 31 13. Department of Biomedical Science, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
- 32 14. Department of Computational Biology for Individualised Infection Medicine, Centre for Individualised
33 Infection Medicine (CiiM) & TWINCORE, joint ventures between the Helmholtz-Centre for Infection
34 Research (HZI) and the Hannover Medical School (MHH), 30625 Hannover, Germany
- 35 15. Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia

36

37 **Abstract**

38 **Background**

39 Cellular metabolism is critical for the host immune function against pathogens, and metabolomic analysis may
40 help understand the characteristic immunopathology of tuberculosis. We performed targeted metabolomic
41 analyses in a large cohort of patients with tuberculous meningitis (TBM), the most severe manifestation of
42 tuberculosis, focusing on tryptophan metabolism.

43 **Methods**

44 We studied 1069 Indonesian and Vietnamese adults with TBM (26.6% HIV-positive), 54 non-infectious
45 controls, 50 with bacterial meningitis, and 60 with cryptococcal meningitis. Tryptophan and downstream
46 metabolites were measured in cerebrospinal fluid (CSF) and plasma using targeted liquid chromatography
47 mass-spectrometry. Individual metabolite levels were associated with survival, clinical parameters, CSF
48 bacterial load and 92 CSF inflammatory proteins.

49 **Results**

50 CSF tryptophan was associated with 60-day mortality from tuberculous meningitis (HR=1.16, 95%CI=1.10-1.24,
51 for each doubling in CSF tryptophan) both in HIV-negative and HIV-positive patients. CSF tryptophan
52 concentrations did not correlate with CSF bacterial load nor CSF inflammation but were negatively correlated
53 with CSF interferon-gamma concentrations. Unlike tryptophan, CSF concentrations of an intercorrelating
54 cluster of downstream kynurenine metabolites did not predict mortality. These CSF kynurenine metabolites
55 did however correlate with CSF inflammation and markers of blood-CSF leakage, and plasma kynurenine
56 predicted death (HR 1.54, 95%CI=1.22-1.93). These findings were mostly specific for TBM, although high CSF
57 tryptophan was also associated with mortality from cryptococcal meningitis.

58 **Conclusion**

59 TBM patients with a high baseline CSF tryptophan or high systemic (plasma) kynurenine are at increased risk of
60 mortality. These findings may reveal new targets for host-directed therapy.

61 **Funding**

62 This study was supported by National Institutes of Health (R01AI145781) and the Wellcome Trust
63 (110179/Z/15/Z and 206724/Z/17/Z).

64

65

66


67 Introduction

68 Tuberculous meningitis (TBM) is the most severe manifestation of tuberculosis affecting approximately
69 160,000 adults each year.¹ Patients suffer from varying degrees of intracerebral inflammation, commonly
70 manifest as leptomeningitis, vasculitis and space-occupying brain lesions (tuberculomas). Hydrocephalus,
71 stroke, seizures, focal neurological deficits, and loss of consciousness are common complications and lead to
72 death in around 30% of patients, even when treated with anti-tuberculosis drugs and adjuvant corticosteroid
73 therapy.¹ Development of more effective host-directed therapy is hampered by a lack of knowledge on the
74 biological pathways involved in the immunopathology of TBM.²

75 Metabolism is critical for the function of immune cells, and analysis of cerebrospinal fluid (CSF) metabolites
76 could help unravel underlying biological mechanisms in TBM. Previously, using a large-scale metabolomics
77 analysis, we found that lower cerebrospinal fluid (CSF) tryptophan concentrations were associated with
78 survival of TBM patients in Indonesia.³ This study did not include HIV-infected patients and the association was
79 not validated in other populations.^{4,5} Moreover, there is a need to investigate the downstream metabolites in
80 the kynurenine pathway (**Figure 1**), through which 95% of tryptophan is initially catabolized via indoleamine
81 2,3-dioxygenase (IDO) or tryptophan 2,3-dioxygenase (TDO) and which includes metabolites with putative
82 neuroprotective (e.g. kynurenic acid) or neurodamaging (e.g. quinolinic acid) properties.⁶ Lastly, there is a
83 need to compare these findings in other neuro-infectious diseases to distinguish disease specific from broader
84 mechanisms.

85 We therefore sought to define and validate the relationship between tryptophan and its metabolites and
86 survival from TBM in large, independent populations, including HIV-positive individuals. We aimed to confirm
87 that a higher CSF tryptophan would predict higher mortality across different populations and we hypothesized
88 that high tryptophan would be associated with a higher CSF bacterial load, more inflammation and lower
89 downstream kynurenine metabolites. We lastly sought to investigate how systemic (plasma) metabolite
90 concentrations linked to outcome.

91



92

93 **Figure 1 Tryptophan metabolism pathway.** Tryptophan is metabolized mainly through the kynurenine
94 pathway through indoleamine 2,3-dioxygenase 1 (IDO1), generating kynurenine and its downstream
95 metabolites (blue box). IDO1 is partly stimulated by *M. tuberculosis*-induced interferon gamma (IFN-γ)
96 production by T helper 1 cells.

97

98 **Materials and Methods**

99 **Setting and Patients**

100 Patients with subacute meningitis were included from the Hospital for Tropical Diseases and Pham Ngoc Thach
101 Hospital for Tuberculosis and Lung Disease in Ho Chi Minh City, Vietnam between 2011-2014,^{4,7} and Hasan
102 Sadikin hospital in Indonesia between 2007-2019.^{3,5} TBM patients were defined as having 'definite TBM' if they
103 had either microbial confirmation by Ziehl-Neelsen staining, positive CSF culture or GeneXpert. Based on
104 previous studies,⁵ probable TBM was defined as clinically suspected TBM fulfilling at least 2 out of the
105 following 3 criteria: CSF leukocytes ≥ 5 cells/ μ L, CSF/blood glucose ratio < 0.5 , and CSF protein > 0.45 g/L.
106 Patients were treated with antibiotics according to national guidelines for 180 days minimally, and received
107 adjunctive dexamethasone starting at 0.3 mg/kg for grade I and 0.4 mg/kg for grade II or III
108 tuberculous meningitis and tapered thereafter.⁸ Patients were followed-up clinically or by phone up until day
109 180 from admission. Primary outcome was 60-day survival, when most deaths attributable to TBM occur. As a
110 secondary endpoint, earlier and later mortality were explored separately. We ensured equal power for both
111 time windows by separating them by the median time to death for those patients who died during the total
112 follow up of 180 days.

113 Patients without an infection (non-infectious controls) were included from the same sites. In Indonesia,
114 patients in this group had undergone a lumbar puncture for suspected central nervous system infection or
115 subarachnoid bleeding, but infection was excluded by negative microscopy, GeneXpert and bacterial culture,
116 and CSF leukocytes < 5 cells/ μ L and CSF/blood glucose ratio ≥ 0.5 . In Vietnam, patients were included as
117 controls if they had undergone a lumbar puncture, but an alternative, non-infectious, diagnosis was confirmed.
118 In both sites, none of the non-infectious controls received anti-tuberculosis treatment. HIV-negative patients
119 with microbiologically confirmed bacterial meningitis and HIV-positive patients with cryptococcal meningitis
120 patients were included from the same sites.

121 Ethical approval was obtained from the Ethical Committee of Hasan Sadikin Hospital, Faculty of
122 Medicine, Universitas Padjadjaran, Bandung, Indonesia and from the Oxford Tropical Research Ethics
123 Committee in the United Kingdom, the Institutional Review Boards of the Hospital for Tropical Diseases and
124 Pham Ngoc Thach Hospital in Vietnam. Written (Vietnam) or oral (Indonesia) consent to be included in the
125 study, for storage of surplus sample, and to obtain follow-up data was obtained from patients or close
126 relatives of patients who were unconscious. The paper adheres to the STROBE methodology.

127 **Metabolite measurements**

128 CSF and blood samples were centrifuged for 15 minutes according to local protocols (865 - 3000 x g) and
129 supernatants were stored at -80°C .⁹ CSF and plasma metabolites were measured using targeted a liquid
130 chromatography tandem mass spectrometry (LC-MS) method with a system comprised of a 1290 Infinity II U-
131 HPLC coupled to an Agilent 6495 Triple Quadrupole mass spectrometer (Agilent Tech. Santa Clara, CA).
132 Metabolites were extracted from plasma or CSF (10 μ L) using 90 μ L of acetonitrile/methanol/formic acid
133 (74.9:24.9:0.2 v/v/v) containing stable isotope-labeled internal standards (valine-d8, Sigma-Aldrich; St. Louis,
134 MO; and phenylalanine-d8, Cambridge Isotope Laboratories, Andover, MA). The samples were centrifuged (10
135 min, 9,000 x g, 4°C), and the supernatants were injected directly onto a 150 x 2 mm, 3 μ m Atlantis HILIC
136 column (Waters; Milford, MA). The column was eluted isocratically at a flow rate of 250 μ L/min with 5%
137 mobile phase A (10 mM ammonium formate and 0.1% formic acid in water) for 0.5 minute followed by a linear
138 gradient to 40% mobile phase B (acetonitrile with 0.1% formic acid) over 10 minutes. Pairs of pooled samples
139 generated using aliquots of all samples in the study were included every 20 samples correct for MS sensitivity
140 drift and for quality control analyses. Sample stability over the 7 years study inclusion and 4-year storage time
141 was checked by plotting metabolite levels of definite TBM patients against storage time. Tryptophan
142 metabolites were measured using the following multiple reaction monitoring transitions: 3-hydroxyanthranilic
143 acid (154.1 \rightarrow 136.0), 3-indoleacetic acid (176.1 \rightarrow 130.1), 3-methoxyanthranilate (168.1 \rightarrow 150.0), 5-
144 hydroxyindoleacetic acid (192.1 \rightarrow 146.0), 5-methoxytryptophol (192.1 \rightarrow 130.0), kynurenic acid (190.1 \rightarrow
145 144.1), kynurenine (209.1 \rightarrow 94.0), tryptophan (205.1 \rightarrow 187.9), N-acetylserotonin (219.1 \rightarrow 160.0),
146 niacinamide (123.1 \rightarrow 80.1), quinolinic acid (168.0 \rightarrow 149.9) and xanthurenic acid (206.1 \rightarrow 132.0). Absolute
147 concentrations were determined using external calibration curves created via serial dilution of stable isotope-
148 labeled compounds in CSF and plasma. These compounds were sourced from Cambridge Isotope Labs: 3-
149 indoleacetic acid-d7 (DLM-8040), anthranilic acid-¹³C6 (CLM-701), 5-HIAA-¹³C6 (CLM-9936), kynurenic acid-d5
150 (DLM-7374), L-kynurenine-d6 ([DLM-7842](#)), L-tryptophan-¹³C11 (CLM-4290) and niacinamide-¹³C6 (CLM-9925).

151 Peak abundances were manually integrated using the MassHunter software provided by the LC-MS
152 manufacturer.

153 **CSF mycobacterial load and inflammatory proteins**

154 The CSF mycobacterial load was inferred qualitatively by comparing patients with negative versus positive CSF
155 culture, and semiquantitatively from the GeneXpert Ct-values as described previously,¹⁰ and inferred from CSF
156 *M. tuberculosis* culture. CSF inflammatory cytokines in 178 Indonesian HIV-negative TBM patients were
157 measured using a multiplex proximity extension assay (Olink) in two batches. Olink uses a multiplex assay that
158 simultaneously recognize 96 target proteins through specific paired-antibodies which are coupled with unique
159 oligonucleotides, for quantitative PCR measurement.¹¹ For each protein, overlapping samples from two
160 batches were fitted in a linear regression model, where the linear components were subsequently extracted,
161 and used as correction factors for batches normalization. In 304 Vietnamese HIV-negative patients, 10 human
162 cytokines were measured in CSF with Luminex multiplex bead array technology (Bio-Rad Laboratories,
163 Hercules, CA).⁴ CSF total protein was used as proxy for blood-CSF barrier disruption as it showed a near-perfect
164 correlation with the established marker CSF-serum albumin ($r^2=0.98$).¹²

165 **Quality control and statistical analysis**

166 Only metabolites and proteins with a coefficient of variation (CV) of the pooled samples < 30% and < 25%
167 missing values, respectively among TBM patients were further included in the analysis. Remaining missing
168 metabolite values after quality control were replaced with half of the minimum measured value of the
169 corresponding metabolite, and log₂-transformed subsequently. Statistical analyses were performed in R
170 4.0.4¹³, using the R packages survival, tableone, dplyr, openxlsx, pheatmap, grid, and ggplot2. Correlation
171 analyses between metabolites levels, and between metabolites levels and clinical and inflammatory
172 parameters, were calculated using spearman-rank correlation. The impact of baseline CSF and plasma
173 metabolite levels on 60-day survival was tested in a Cox-regression model, adjusted for sex, age, and HIV
174 status as covariates. The model stratified by study site as mortality is known to be higher in the Indonesian⁵
175 than in the Vietnamese⁷ cohort. An analysis plan was made before the study, and correction for multiple
176 testing using the Benjamini Hochberg method was done if multiple comparisons were done in primary
177 analysis.

178

179

180 **Results**

181 **Baseline characteristics of TBM patients and controls**

182 We studied 1069 adults with TBM, 390 from Indonesia and 679 from Vietnam (**Table 1**). Patients were young
183 (median age 34 years), 26.6% were HIV-positive, and the majority presented with a moderately severe (55.6 %
184 grade II) to severe (17.0% grade III) severe disease according to the international classification.¹⁴ The rate of
185 mycobacterial confirmation was 64.1%. Sixty-day mortality, the primary endpoint in the analysis, was 21.6%.
186 Patients who died within 180 days from admission did so after a median of 14 days. A 14-day cut-off was
187 therefore used to distinguish early from late mortality as a secondary endpoint.

	Tuberculous meningitis (n=1069)	Non-infectious control (n=54)	Bacterial meningitis ¹ (n=50)	Cryptococcal meningitis ¹ (n=60)
Clinical features				
Age, years	34 (27-44)	35 (25- 44)	46 (34- 57)	33 (27- 37)
sex - % male	700 (65.5%)	30 (55.6%)	12 (60.0%)	26 (78.8%)
Glasgow Coma Scale	14 (12-15)	15 (12-15)	13 (9-14)	15 (13-15)
HIV - % positive	284 (26.6%)	11 (20.4%)	0 (0%)	60 (100%)
Tuberculous meningitis grade (%)				

188 **Table 1: Patient baseline characteristics.**

Grade I	287 (27.3%)	-	-	-
Grade II	584 (55.6%)	-	-	-
Grade III	179 (17.0%)	-	-	-
Cerebrospinal fluid features				
Leukocytes- cells per μ L	150 (49-336)	2 (1-3)	1900 (739-5460)	86 (24-192)
Neutrophils- cells per μ L	22 (3-99)	1 (0-1)	1527 (538-4986)	17 (6-109)
Mononuclear cells- cells per μ L	98 (38-207)	2 (1-3)	307 (134-646)	31 (6-89)
Protein- g/L	1.46 (0.90-2.40)	0.40 (0.26-0.59)	1.90 (1.10-3.80)	0.76 (0.58-1.60)
CSF to blood glucose ratio	0.28 (0.17-0.40)	0.60 (0.56-0.70)	0.46 (0.17-1.00)	0.50 (0.30-1.00]
<i>M. tuberculosis</i> culture or ZN-staining or GeneXpert positive	686 (64.17%)	-	-	-
Outcomes				
Outcome at day 60				
Alive	825 (77.2%)	-	-	-
Deceased	231 (21.6%)	-	-	-
Lost to follow-up	13 (1.2%)	-	-	-
Outcome at day 180				
Alive	731 (68.4%)	-	-	-
Deceased	304 (28.4%)	-	-	-
Lost to follow-up	34 (3.2%)	-	-	-

189 *Legend: categorical variables are presented in N (%); Continuous variables are presented in median (IQR).*
 190 *Abbreviations: CSF=cerebrospinal fluid. ¹Clinical metadata available for 40% of bacterial meningitis and 56% of*
 191 *cryptococcal meningitis patients.*


192 There were some differences between the populations. Indonesian patients presented with more severe
 193 diseases (91.9% grade with grade II or III) than Vietnamese patients (62.2%). Also, CSF total protein, a proxy for
 194 blood-CSF barrier leakage,¹² was higher in Indonesian (median=1.6 g/L, IQR=0.8-3.1) than Vietnamese (1.3 g/L,
 195 IQR=0.8-2.0) patients. CSF polymorphonuclear cell counts were higher in the Indonesian than in the
 196 Vietnamese patients where it showed a bimodal distribution associated to study site (**Supplementary Figure 1**)
 197 and stratified analyses were performed taking this into account. Compared to the TBM patients, non-
 198 infectious controls (n=54), bacterial meningitis patients (n=50), and cryptococcal meningitis patients (n=60)
 199 had a similar age range and gender distribution.

200 Ten metabolites showed detectable levels in >75% of patients and passed quality control, while two
 201 metabolites, 3-methoxyanthranilate and 5-hydroxyindoleacetic acid, were detected in less than 75% of
 202 patients and excluded from further analysis. Metabolite measurements showed stable concentrations over
 203 and were not affected by year of patient inclusion and duration of sample (**Supplementary Figure 2**).

204

205 **Increased CSF tryptophan levels were associated with mortality of TBM patients independent of HIV status**
 206 Confirming our previous findings,³ higher baseline CSF tryptophan levels predicted 60-day survival in patients
 207 with TBM (HR=1.16 for each doubling in CSF tryptophan, 95%CI=1.10-1.24), all analyses corrected for age, sex
 208 and HIV status, and stratified for cohort, **Figure 2, Table 2**). This was both true for HIV-negative (HR=1.13,
 209 95%CI=1.05-1.21) and HIV-positive patients (HR=1.19, 95%, CI=1.07-1.33), who showed a much higher
 210 mortality (**Supplementary Figure 3**), as reported previously.^{4,5} Baseline CSF tryptophan was associated with
 211 both early (HR=1.14, 95%CI=1.06-1.23) and late (HR=1.17, 95%CI=1.08-1.26) mortality (**Supplementary Table**
 212 **1**). Compared to non-infectious controls, CSF tryptophan was lower. This was also observed in patients with
 213 cryptococcal, but not in those with bacterial meningitis (**Figure 3**). Interestingly, among 17 cryptococcal
 214 meningitis patients with available in-hospital mortality data in Indonesia, baseline CSF tryptophan was
 215 significantly higher in those who died in hospital compared to those discharged alive (**Supplementary Figure**
 216 **4**), similar as in TBM.

217



218

219 **Figure 2 Six-months survival curve of TBM patients.** Patients were stratified by CSF tryptophan concentrations
220 tertiles.

221

222

223 **Table 2 Univariate Cox regression for 60-day mortality for CSF metabolites**

Metabolites	HR ¹	95% CI ¹	p-value	FDR ²
tryptophan	1.16	1.10, 1.24	<0.001	<0.001
kynurenine	1.00	0.93, 1.07	>0.9	>0.9
kynurenic acid	1.00	0.93, 1.07	0.9	>0.9
3-hydroxyanthranilic acid	1.01	0.97, 1.05	0.6	0.9
xanthurenic acid	0.95	0.90, 1.00	0.05	0.2
quinolinic acid	0.92	0.85, 1.00	0.038	0.2
niacinamide	1.03	0.95, 1.11	0.5	0.8
3-indoleacetic acid	1.11	0.96, 1.29	0.2	0.4
N-acetylserotonin	1.01	0.94, 1.09	0.7	0.9
5-methoxytryptophol	1.11	0.93, 1.32	0.3	0.5

224 *Legend: Cox regression models were stratified by cohort and adjusted by sex, age, and HIV status. Hazard ratio*
225 *(HR) was calculated per 2-fold increase in metabolite concentration. ¹ HR = Hazard ratio, CI = Confidence*
226 *interval. ² FDR=False Discovery Rate; Benjamini & Hochberg correction for multiple testing.*

227


228 **CSF tryptophan levels do not reflect mycobacterial burden**

229 We next examined if CSF tryptophan was associated with CSF mycobacterial load. We hypothesized that a low
230 baseline tryptophan might either reflect a lower bacterial load, as *M. tuberculosis* can produce tryptophan, or
231 might cause a lower bacterial load as tryptophan depletion impairs mycobacterial growth.⁷⁹ Instead, we found
232 a reverse, albeit weak relationship: tryptophan was higher in CSF culture negative (median=0.31 μ M) than
233 culture positive (median=0.14 μ M, $p<0.001$) TBM patients. Similarly, among patients with CSF GeneXpert-
234 confirmed tuberculous meningitis patients, we did not find a correlation between CSF tryptophan and
235 quantitative PCR results (Spearman's $\rho=0.084$, $p=0.105$, **Supplementary Figure 5**). Interestingly, within
236 patients with microbiologically confirmed TBM the effect of tryptophan was stronger (HR=1.28, 95%CI=1.17-
237 1.40) than in patients with probable TBM (HR=1.07, 95%CI=0.98-1.18).

238

239 **Relationship between cerebral and systemic metabolism and its impact on survival**

240 Ninety-five percent of tryptophan is converted to kynurenine⁶ and we therefore hypothesized that lower CSF
241 tryptophan levels in TBM are caused by higher conversion to kynurenine, and that the higher CSF tryptophan
242 associated with death could reflect reduced activity of IDO1 and other downstream enzymes. CSF kynurenine
243 (**Figure 3**) and its downstream metabolite kynurenic acid (**Supplementary Figure 6**) were higher in TBM
244 patients, bacterial meningitis and cryptococcal meningitis patients compared to non-infectious controls, but
245 not significantly different between surviving and non-surviving TBM patients (**Table 2**).




246

247 **Figure 3 CSF and plasma metabolites concentrations in TBM and controls for the tryptophan metabolites**
248 **associated with outcome: tryptophan and kynurenine. (A) Relative concentrations based on peak ion intensity**
249 **(B) absolute concentrations in μM .**

250

251 Then, to examine the relation between cerebral and systemic tryptophan metabolism, we compared
252 concentrations of CSF metabolites with those in plasma, measured in a subset of 300 TBM patients. In contrast
253 to our findings in CSF, plasma tryptophan levels were higher and kynurenine levels were lower in TBM patients
254 compared to controls. As the CSF kynurenine metabolites positively correlated with CSF protein (**Figure 4**), a
255 proxy for barrier leakage¹², we hypothesized that systemic leakage might be an additional source of
256 kynurenine. For a subset of metabolites, absolute quantification of metabolite levels was achieved. This
257 showed that the increase in CSF kynurenine in TBM patients ($\Delta = 3.52 \mu\text{M}$) was much more marked than the
258 decrease in CSF tryptophan ($\Delta = 0.39 \mu\text{M}$, **Figure 3B**). Corroborating our leakage hypothesis, the CSF-plasma
259 gradient of the kynurenine metabolites showed strong correlations with total CSF protein (**Supplementary**
260 **Figure 7**). Plasma tryptophan did not predict mortality, but plasma levels of its downstream metabolites
261 kynurenine strongly predicted mortality (**Supplementary Table 2**).



262


263 **Figure 4 Correlation between tryptophan metabolites and with clinical and CSF parameters.** Significant
 264 Spearman's correlation coefficients are presented in the correlation matrix, while the ones with not significant
 265 correlations were blank. Red indicates positive correlations, and blue indicates negative ones. The color
 266 gradient shows the strength of the associations.

267

268 **CSF tryptophan is inversely correlated with interferon-gamma**

269 We next looked at correlations of tryptophan metabolites and inflammation, as inflammation is a determinant
270 of outcome from TBM.² Out of 92 inflammatory proteins measured in CSF from 176 TBM patients from
271 Indonesia, 80 proteins were detectable in >75% of patients. Tryptophan correlated inversely to a small cluster
272 of 13 cytokines, including interferon gamma (IFN- γ , **Supplementary Figure 8**). In line with this finding, a higher
273 CSF IFN- γ has previously been shown to predict survival of Vietnamese TBM patients.⁴ IFN- γ is known to induce
274 IDO1¹⁵, which converts tryptophan to kynurenine. We indeed confirmed the inverse correlation between CSF
275 tryptophan and IFN- γ in our Vietnamese patients (Spearman's ρ =-0.45, p <0.0001, **Figure 5A**), irrespective of
276 HIV-status. Different from tryptophan, the kynurenine metabolites (kynurenine, kynurenic acid, 3-
277 hydroxyanthranilic acid, and quinolinic acid) correlated strongly with a large cluster of inflammatory proteins
278 including the hallmark inflammatory protein TNF- α , which we could again confirm in the Vietnamese patients
279 (Spearman's ρ =0.30, p <0.0001, **Figure 5B**).

280



281

282 **Figure 5 Associations of CSF tryptophan with IFN- γ (A) and with TNF- α (B) in 176 Indonesian (left) and 304**
283 **(Vietnamese) TBM patients. The boxplots on the left of each plot show the association of metabolites with**
284 **cytokines below the detection limit. Abbreviations: IFN- γ : interferon gamma, TNF- α : tumor necrosis factor**
285 **alpha, LOD: lower limit of detection.**

286

287

288

289 Discussion

290 We previously found that CSF concentrations of tryptophan were lower in HIV-negative Indonesian adults with
291 TBM compared to non-infectious controls, and that TBM patients with lower tryptophan levels had lower
292 mortality.³ In the current study we confirm these observations in a much larger cohort of HIV-negative and
293 positive patients from both Vietnam and Indonesia. Aiming to understand how tryptophan metabolism is
294 altered in TBM and how it might exert its effect on patient outcome, we correlated its concentrations with
295 bacterial load and CSF inflammatory markers and measured downstream metabolites both in CSF and plasma.
296 Our findings show that CSF concentrations of downstream kynurenine metabolites did not predict mortality,
297 and that higher tryptophan levels were not associated with a higher bacterial load. Also, while kynurenine
298 metabolites strongly correlated with CSF inflammatory markers and CSF protein, a marker of blood-CSF
299 leakage, there was no association with CSF tryptophan. A higher tryptophan did however show a strong
300 negative correlation with IFN- γ , important for immunity against mycobacteria. Collectively, these findings
301 suggest that tryptophan affects outcome from TBM within the brain rather than systemically. This is
302 potentially driven by IFN- γ but not associated with nonspecific inflammation, and independent from
303 downstream tryptophan metabolism or bacterial replication. In contrast, kynurenine may affect outcome
304 systemically by leakage across the blood-brain barrier.

305 CSF tryptophan increases with age in individuals without central nervous system infections.¹⁶ Age is known to
306 negatively impact outcome of TBM^{4,5} and in this study, higher age was associated with higher CSF tryptophan
307 concentrations. All mortality analyses were therefore corrected for age, as well as sex and HIV-status, and
308 analysis was stratified for country because of the overall higher mortality in Indonesian compared to
309 Vietnamese tuberculous meningitis patients.^{4,5} We further tested whether higher CSF tryptophan reflected a
310 higher mycobacterial burden and refuted this hypothesis. For cryptococcal meningitis, no previous data on
311 cerebral tryptophan metabolism was known. These patients follow a pattern similar to TBM, with low
312 tryptophan and high kynurenine, and in a small number of cryptococcal meningitis patients, a high baseline
313 CSF tryptophan predicted mortality, similar ss for TBM.

314 Systemic tryptophan and kynurenine are transported into the brain over the large amino acid transporter
315 *LAT1*. In a healthy brain, systemic and CSF kynurenine positively correlate, as do CSF concentrations of
316 tryptophan and kynurenine.¹⁶ In patients with cerebral inflammation, the correlation between CSF kynurenine
317 and tryptophan can be lost, probably through increased catabolism through IDO upregulation, which also has
318 been demonstrated in the brain parenchyma of deceased TBM patients.¹⁸ Although we found low CSF
319 tryptophan and high CSF kynurenine in TBM compared to healthy controls, the two did not intercorrelate and
320 moreover, the increase in CSF kynurenine was much larger than the decrease in CSF tryptophan and it is
321 therefore unlikely that upregulation of IDO1 solely explains this which precludes catabolism as the sole
322 explanation. This suggests that increased blood to central nervous system transport as an additional
323 mechanism to IDO1 upregulation. Endothelial cells and pericytes of the blood-brain-barrier can upregulate
324 tryptophan catabolism into kynurenine metabolites upon IFN- γ stimulation.¹⁹ Our findings corroborate this
325 hypothesis because we find a strong negative correlation between CSF IFN- γ and CSF tryptophan in our
326 patients.

327 We examined whether higher CSF tryptophan concentrations reflected higher concentrations of downstream
328 kynurenine metabolites that may have neurotoxic (quinolinic acid) or lower levels of the metabolites that may
329 have neuroprotective (kynurenic acid) properties⁶ and refuted these hypotheses. Interestingly however, CSF
330 kynurenine metabolites correlated with CSF cell counts and pro-inflammatory proteins, including TNF- α .
331 Kynurenine is sensed by the aryl hydrocarbon receptor (AhR), which is important for the upregulation of TNF
332 among other pro-inflammatory cytokines in a mouse model,²⁰ in line with our CSF findings. The increased CSF
333 kynurenine levels we found in TBM have been reported before in bacterial meningitis^{21,22} and in cerebral
334 malaria²³ and in plasma from pulmonary TB patients.¹⁷ Of interest, nicotinamide can inhibit *M. tuberculosis*
335 growth, and can compete with isoniazid for antimycobacterial effects.²⁴ We did however not find a
336 detrimental effect of a higher nicotinamide, possibly because of its complex biology, i.e. it can also be
337 produced by *M. tuberculosis* when human dietary niacin intake is limited.²⁵

338 Strengths of our study include the large numbers of clinically well-phenotyped patients from multiple
339 independent study sites in Indonesia and Vietnam, including a significant proportion of HIV-positive patients.
340 We moreover used a sensitive triple quadrupole (QQQ) mass spectrometry method specifically designed to

341 accurately target the tryptophan metabolites. Absolute quantification of a subset of metabolites further
342 facilitated interpretation. Due to differences in polarity of the downstream tryptophan metabolites, we could
343 not measure the complete tryptophan pathway. The availability of CSF at baseline only, limits our ability to
344 understand how changes in tryptophan metabolism influence mortality. And we infer our observations from
345 lumbar CSF, which reflects biological processes from both the blood and the brain. The use of ventricular CSF
346 and potentially animal models, could help establishing what processes in the brain parenchyma take place.
347 Animal studies are warranted to see whether pharmacological induction of IDO1 (for instance with
348 recombinant IFN- γ), or inhibitory tryptophan analogues²⁶ should be priorities as adjuvant therapeutic
349 candidates for future personalized trials.

350 In summary, we confirm the importance of CSF tryptophan to outcome from HIV-negative and HIV-positive
351 adults with TBM, independent from downstream kynurenine metabolism, bacterial load and inflammation. We
352 additionally show the potential importance of systemic kynurenine as a predictor of mortality. Better
353 understanding of the metabolic pathways associated with TBM may lead to more targeted therapies, as
354 adjuvant immunotherapy may modulate the aberrant metabolic pathways and thus improve outcome.

355

356 **Materials availability**

357 The clinical metadata and LC-MS data before pre-processing is available as Supplementary File to this
358 manuscript.

359

360 **Acknowledgements**

361 The authors thank the neurology residents and Tiara Pramaesya, Sofia Immaculata, Putri Andini, Sri Margi,
362 Rani Trisnawati and Shehika Shulda of the tuberculous meningitis study team for monitoring patients and data
363 management; Lidya Chaidir and Jessi Annisa for mycobacterial diagnostics; the director of the Hasan Sadikin
364 General Hospital, Bandung, Indonesia, for accommodating the research. We also express our gratitude to our
365 funders: This study was supported by National Institutes of Health (R01AI145781), the Wellcome Trust
366 (110179/Z/15/Z and 206724/Z/17/Z). Previous establishment of the cohorts in Indonesia was supported by the
367 Direktorat Jendral Pendidikan Tinggi (BPPLN fellowship to SD) and the Ministry of Research, Technology, and
368 Higher Education, Indonesia (PKSLN grant to THA, RR, and SD), and United States Agency for International
369 Development (PEER Health grant to RR). The funders had no role in study design, data collection and analysis,
370 decision to publish, or preparation of the manuscript.

371

372 References

373

- 374 1 Dodd PJ, Osman M, Cresswell FV, *et al.* The global burden of tuberculous meningitis in adults: A modelling
375 study. *Plos Global Public Heal* 2021; 1: e0000069.
- 376 2 Wilkinson RJ, Rohlwink U, Misra UK, *et al.* Tuberculous meningitis. *Nat Rev Neurol* 2017; 13: 581–98.
- 377 3 Laarhoven A van, Dian S, Aguirre-Gamboa R, *et al.* Cerebral tryptophan metabolism and outcome of
378 tuberculous meningitis: an observational cohort study. *The Lancet Infectious Diseases* 2018; 18: 526–35.
- 379 4 Thuong NTT, Heemskerck D, Tram TTB, *et al.* Leukotriene A4 Hydrolase Genotype and HIV Infection Influence
380 Intracerebral Inflammation and Survival From Tuberculous Meningitis. *Journal of Infectious Diseases* 2017;
381 215: 1020–8.
- 382 5 Laarhoven A van, Dian S, Ruesen C, *et al.* Clinical Parameters, Routine Inflammatory Markers, and LTA4H
383 Genotype as Predictors of Mortality Among 608 Patients With Tuberculous Meningitis in Indonesia. *J Infect Dis*
384 2017; 215: 1029–39.
- 385 6 Lovelace MD, Varney B, Sundaram G, *et al.* Recent evidence for an expanded role of the kynurenine pathway
386 of tryptophan metabolism in neurological diseases. *Neuropharmacology* 2017; 112: 373–88.
- 387 7 Heemskerck AD, Bang ND, Mai NTH, *et al.* Intensified Antituberculosis Therapy in Adults with Tuberculous
388 Meningitis. *N Engl J Med* 2016; 374: 124–34.
- 389 8 Thwaites GE, Nguyen DB, Nguyen HD, *et al.* Dexamethasone for the treatment of tuberculous meningitis in
390 adolescents and adults. *N Engl J Med* 2004; 351: 1741–51.
- 391 9 Rohlwink UK, Chow FC, Wasserman S, *et al.* Standardized approaches for clinical sampling and endpoint
392 ascertainment in tuberculous meningitis studies. *Wellcome Open Res* 2019; 4: 204.
- 393 10 Thuong NTT, Vinh DN, Hai HT, *et al.* Pretreatment Cerebrospinal Fluid Bacterial Load Correlates With
394 Inflammatory Response and Predicts Neurological Events During Tuberculous Meningitis Treatment. *Journal of*
395 *Infectious Diseases* 2019; 219: 986–95.
- 396 11 Assarsson E, Lundberg M, Holmquist G, *et al.* Homogenous 96-plex PEA immunoassay exhibiting high
397 sensitivity, specificity, and excellent scalability. *PLoS ONE* 2014; 9: e95192.
- 398 12 Svensson EM, Dian S, Brake LT, *et al.* Model-based meta-analysis of rifampicin exposure and mortality in
399 Indonesian tuberculosis meningitis trials. *Clin Infect Dis* 2019; published online Oct 30.
400 DOI:10.1093/cid/ciz1071.
- 401 13 Team RC. R: A language and environment for statistical computing. R Foundation for Statistical Computing.
402 Vienna, Austria, 2022 <https://www.R-project.org/>.
- 403 14 Thwaites GE, Simmons CP, Quyen NTH, *et al.* Pathophysiology and prognosis in vietnamese adults with
404 tuberculous meningitis. *Journal of Infectious Diseases* 2003; 188: 1105–15.
- 405 15 Zhang YJ, Reddy MC, Ioerger TR, *et al.* Tryptophan Biosynthesis Protects Mycobacteria from CD4 T-Cell-
406 Mediated Killing. *Cell* 2013; 155: 1296–308.
- 407 16 Hestad KA, Engedal K, Whist JE, Farup PG. The Relationships among Tryptophan, Kynurenine, Indoleamine
408 2,3-Dioxygenase, Depression, and Neuropsychological Performance. *Front Psychol* 2017; 8: 1561.
- 409 17 Weiner J, Maertzdorf J, Sutherland JS, *et al.* Metabolite changes in blood predict the onset of tuberculosis.
410 *Nat Comms* 2018; : 1–12.
- 411 18 Kumar GS, Venugopal AK, Selvan LDN, Marimuthu A, Keerthikumar S. Gene Expression Profiling of
412 Tuberculous Meningitis. *JPB* 2011; 04. DOI:10.4172/jpb.1000174.
- 413 19 Owe-Young R, Webster NL, Mukhtar M, *et al.* Kynurenine pathway metabolism in human blood–brain–
414 barrier cells: implications for immune tolerance & neurotoxicity. *J Neurochem* 2008; 105: 1346–57.

- 415 20 Moura-Alves P, Faé K, Houthuys E, *et al.* AhR sensing of bacterial pigments regulates antibacterial defence.
416 *Nature* 2014; 512: 387–92.
- 417 21 Coutinho LG, Christen S, Bellac CL, *et al.* The kynurenine pathway is involved in bacterial meningitis. *J*
418 *Neuroinflamm* 2014; 11: 169.
- 419 22 Sühs K-W, Novoselova N, Kuhn M, *et al.* Kynurenine Is a Cerebrospinal Fluid Biomarker for Bacterial and
420 Viral Central Nervous System Infections. *J Infect Dis* 2019; 220: 127–38.
- 421 23 Medana IM, Day NPJ, Salahifar-Sabet H, *et al.* Metabolites of the kynurenine pathway of tryptophan
422 metabolism in the cerebrospinal fluid of Malawian children with malaria. *Journal of Infectious Diseases* 2003;
423 188: 844–9.
- 424 24 Murray MF. Nicotinamide: An Oral Antimicrobial Agent with Activity against Both Mycobacterium
425 tuberculosis and Human Immunodeficiency Virus. *Clin Infect Dis* 2003; 36: 453–60.
- 426 25 Adu-Gyamfi CG. Indoleamine 2, 3-Dioxygenase-Mediated Tryptophan Catabolism: A Leading Star or
427 Supporting Act in the Tuberculosis and HIV Pas-de-Deux? *Front Cell Infect Microbiol* 2019; 9: 1–12.
- 428 26 Wang X, Mehra S, Kaushal D, Veazey RS, Xu H. Abnormal Tryptophan Metabolism in HIV and
429 Mycobacterium tuberculosis Infection. *Front Microbiol* 2021; 12: 666227.
- 430
- 431

432 **Supplementary**

433

434


435

436

437

438


439



440 **Supplementary Figure 1 CSF parameters of TBM patients in Indonesia and Vietnam.** Distributions of
441 leukocytes, polymorphonuclear cells, mononuclear cells, protein, and the ratio of CSF/blood glucose in
442 Indonesian (purple) and Vietnamese (yellow) patients are depicted by violin plots.

443

444



445

446 **Supplementary Figure 2 Stability of metabolites over-time.** The concentrations of tryptophan metabolites (in
447 \log_2 scale) were measured in CSF samples from Indonesian (purple) and Vietnamese (yellow) TBM patients
448 were recruited between 2007-2018.


449

450

451

452

453




454

455

456 **Supplementary Figure 3** Six-month survival curve of TBM patients stratified by HIV status. Patients were
 457 stratified by tertiles based on CSF tryptophan concentrations (red=high tryptophan, gray=intermediate
 458 tryptophan, blue=low tryptophan)

459

460




461

462 **Supplementary Figure 4 In-hospital mortality for 17 HIV-positive patients with cryptococcal meningitis.**

463

464




465

466 **Supplementary Figure 5 CSF tryptophan distributions according to mycobacterial load.** (A) comparing CSF
467 culture negative versus positive patients and (B) among patients with a positive CSF Xpert, in culture positive
468 and culture negative TBM patients, CSF tryptophan was associated with CSF Xpert Ct-values from a low (high
469 Ct-value) to low (low Ct-value) load.

470

471

472




473

474 **Supplementary Figure 6** Boxplots of CSF and plasma metabolites concentrations in TBM and controls.
475 Relative concentrations based on peak ion intensities are shown. CSF and plasma concentrations are not
476 directly comparable.

477

478



479


480 **Supplementary Figure 7 Associations between CSF/plasma metabolite ratios (y-axis) and CSF protein levels**
481 **(as a proxy of CSF barrier leakage, x-axis).** Of note, 71 patients had undetectable plasma levels of 3-
482 indoleacetic acid and were removed from this graph.

483

484

485

486



487

488 **Supplementary Figure 8 Correlation between CSF tryptophan metabolites and inflammatory markers**
489 **measured with O-link.** Inflammatory markers were clustered based on their correlation coefficients using
490 hierarchical clustering. Red indicates positive correlation, and blue indicated negative correlation.

491

492

493

494

495 **Supplementary Table 1 Univariate Cox regression for influence CSF metabolites on early and late mortality**

Metabolite	Early mortality (day 0-14)				Late mortality (day 14-180)			
	HR ¹	95% CI ¹	p-value	FDR ²	HR ¹	95% CI ¹	p-value	FDR ²
tryptophan	1.14	1.06, 1.23	<0.001	0.005	1.17	1.08, 1.26	<0.001	<0.001
kynurenine	1.03	0.95, 1.13	0.4	0.6	1	0.91, 1.10	>0.9	>0.9
kynurenic acid	1.05	0.96, 1.14	0.3	0.5	0.95	0.86, 1.04	0.3	0.5
3-hydroxyanthranilic acid	1.02	0.97, 1.06	0.5	0.6	1.01	0.96, 1.06	0.6	0.7
xanthurenic acid	0.96	0.90, 1.03	0.2	0.5	0.96	0.89, 1.04	0.3	0.5
quinolinic acid	0.89	0.81, 0.98	0.02	0.1	0.9	0.81, 1.00	0.052	0.2
niacinamide	1.02	0.92, 1.12	0.7	0.7	1.05	0.95, 1.16	0.3	0.5
3-indoleacetic acid	1.1	0.92, 1.32	0.3	0.5	1.18	0.97, 1.43	0.093	0.2
N-acetylserotonin	1.05	0.96, 1.14	0.3	0.5	0.96	0.88, 1.06	0.4	0.5
5-methoxytryptophol	1.09	0.87, 1.35	0.5	0.6	1.29	1.04, 1.59	0.02	0.1

496 *Cox regression models were stratified by sites and adjusted by age, sex, and GCS.* ¹ HR = Hazard Ratio, CI =
 497 *Confidence Interval.* ² Benjamini & Hochberg correction for multiple testing.

498

499

500

501 **Supplementary Table 2 Univariate Cox regression for influence of plasma metabolites on 60-day mortality**

Metabolite	HR ¹	95% CI ¹	p-value	FDR ²
Tryptophan	0.8	0.56, 1.16	0.2	0.4
Kynurenine	1.54	1.22, 1.93	<0.001	0.002
kynurenic acid	1.2	1.01, 1.43	0.036	0.2
3-hydroxyanthranilic acid	1.13	1.00, 1.28	0.045	0.2
xanthurenic acid	1.11	0.98, 1.25	0.1	0.3
quinolinic acid	0.99	0.88, 1.12	0.9	0.9
Niacinamide	0.92	0.79, 1.07	0.3	0.4
3-indoleacetic acid	1.04	0.97, 1.12	0.3	0.4
N-acetylserotonin	1.05	0.91, 1.22	0.5	0.6
5-methoxytryptophol	1.04	0.85, 1.28	0.7	0.8

502 *Plasma tryptophan metabolites were measured in a subset 300 patients. Cox regression models were stratified*
 503 *by sites and adjusted by age, sex, and GCS.* ¹ HR = Hazard Ratio, CI = Confidence Interval. ² Benjamini &
 504 *Hochberg correction for multiple testing.*